{"id":"amlodipine-plus-hydrochlorothiazide","safety":{"commonSideEffects":[{"rate":"5-10","effect":"Peripheral edema"},{"rate":"5-8","effect":"Headache"},{"rate":"3-5","effect":"Dizziness"},{"rate":"2-5","effect":"Hypokalemia"},{"rate":"2-4","effect":"Hyperglycemia"},{"rate":"2-3","effect":"Flushing"},{"rate":"2-3","effect":"Fatigue"}]},"_chembl":{"chemblId":"CHEMBL1200402","moleculeType":"Small molecule","molecularWeight":"567.06"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Amlodipine is a dihydropyridine calcium channel blocker that inhibits L-type calcium channels in vascular smooth muscle, causing vasodilation and reduced peripheral resistance. Hydrochlorothiazide is a thiazide diuretic that inhibits the sodium-chloride cotransporter in the distal convoluted tubule, promoting natriuresis and reducing circulating blood volume. The combination provides complementary antihypertensive effects through different mechanisms.","oneSentence":"Amlodipine relaxes blood vessels by blocking calcium channels, while hydrochlorothiazide reduces blood volume by increasing sodium and water excretion through the kidneys, together lowering blood pressure.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:21:40.586Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hypertension"}]},"trialDetails":[{"nctId":"NCT07458880","phase":"NA","title":"Triple Antihypertensive Medication After Intracerebral Hemorrhage for Blood Pressure Control","status":"RECRUITING","sponsor":"The University of Hong Kong","startDate":"2026-03-01","conditions":"Intracerebral Hemorrhage","enrollment":140},{"nctId":"NCT06041529","phase":"PHASE4","title":"Study to Evaluate the Efficacy and Safety of TEL/AML/CTD in Elderly Patients With Essential Hypertension","status":"ACTIVE_NOT_RECRUITING","sponsor":"Yuhan Corporation","startDate":"2023-10-18","conditions":"Essential Hypertension","enrollment":198},{"nctId":"NCT05609513","phase":"NA","title":"Integration of Hypertension Management in HIV Care in Uganda","status":"COMPLETED","sponsor":"Infectious Diseases Research Collaboration, Uganda","startDate":"2023-02-06","conditions":"HIV/AIDS, Hypertension","enrollment":87421},{"nctId":"NCT02373163","phase":"PHASE4","title":"INTERVENCION Trial","status":"COMPLETED","sponsor":"Prevencion","startDate":"2014-09-01","conditions":"Blood Pressure, High","enrollment":166},{"nctId":"NCT05920005","phase":"PHASE3","title":"Candesartan Cilexetil + Chlorthalidone + Amlodipine Versus Exforge HCT®️ for Systemic Arterial Hypertension","status":"COMPLETED","sponsor":"Hospital Israelita Albert Einstein","startDate":"2023-08-22","conditions":"Hypertension","enrollment":702},{"nctId":"NCT06790927","phase":"NA","title":"Standardized Antihypertensive Treatment Protocol","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Jiao Tong University School of Medicine","startDate":"2025-02-24","conditions":"Hypertension","enrollment":400},{"nctId":"NCT00140959","phase":"PHASE4","title":"Losartan and HCTZ and Amlodipine vs Atenolol and Amlodipine (0954A-309)(COMPLETED)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2003-02-01","conditions":"Hypertension","enrollment":120},{"nctId":"NCT06366386","phase":"","title":"Integrating Hypertension Management in DSD for HIV","status":"NOT_YET_RECRUITING","sponsor":"Infectious Diseases Research Collaboration, Uganda","startDate":"2024-06-15","conditions":"Hypertension, HIV","enrollment":1100},{"nctId":"NCT06395194","phase":"PHASE3","title":"Effects of Valsartan vs Amlodipine and Low BP on Kidney Outcomes in Essential Hypertension","status":"COMPLETED","sponsor":"Oslo University Hospital","startDate":"1997-09-27","conditions":"Essential Hypertension","enrollment":15313},{"nctId":"NCT00170950","phase":"PHASE3","title":"Avoiding Cardiovascular Events Through Combination Therapy in Patients Living With Systolic Hypertension","status":"TERMINATED","sponsor":"Novartis","startDate":"2003-10","conditions":"Hypertension","enrollment":11506},{"nctId":"NCT02046395","phase":"PHASE4","title":"Effect of Renin-angiotensin-system Blockade on Urinary Free Light Chains in Patients With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Tulane University School of Medicine","startDate":"2012-01","conditions":"Type 2 Diabetes, Hypertension","enrollment":28},{"nctId":"NCT00656331","phase":"NA","title":"The Pleiotropic Effects of Atorvastatin When Combined With Common Antihypertenisve Medications.","status":"WITHDRAWN","sponsor":"University of New Mexico","startDate":"2005-08","conditions":"Hypertension","enrollment":""},{"nctId":"NCT03461003","phase":"PHASE4","title":"N-of-1 Trials In Children With Hypertension","status":"COMPLETED","sponsor":"The University of Texas Health Science Center, Houston","startDate":"2018-04-02","conditions":"Pediatric Hypertension","enrollment":49},{"nctId":"NCT03205137","phase":"","title":"Comparison of the Medication Adherence of Patients Treated With Telmisartan/Hydrochlorothiazide or Telmisartan/Amlodipine Fixed Dose Combination (FDC) Versus Double-pill Combination Therapy in Real-world Japanese Therapeutic Practice","status":"WITHDRAWN","sponsor":"Boehringer Ingelheim","startDate":"2022-06-01","conditions":"Hypertension","enrollment":""},{"nctId":"NCT00142584","phase":"PHASE3","title":"Evaluation of the Long-term Safety and Tolerability of Metoprolol Versus Nebivolol in Patients With Hypertension","status":"COMPLETED","sponsor":"Mylan Bertek Pharmaceuticals","startDate":"2005-08","conditions":"Hypertension","enrollment":336},{"nctId":"NCT02774460","phase":"PHASE4","title":"The Precision Hypertension Care Study","status":"COMPLETED","sponsor":"Uppsala University","startDate":"2017-02-20","conditions":"Hypertension","enrollment":280},{"nctId":"NCT02742467","phase":"PHASE4","title":"Comparison of Three Combination Therapies in Lowering Blood Pressure in Black Africans","status":"COMPLETED","sponsor":"University of Abuja","startDate":"2017-06-07","conditions":"Hypertension","enrollment":702},{"nctId":"NCT04952051","phase":"PHASE3","title":"Enalapril Folic Acid Tablets Combined With CCB or Diuretic to Prevent Stroke in Patients With Type H Hypertension","status":"COMPLETED","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2014-07-01","conditions":"Hypertension","enrollment":1000},{"nctId":"NCT00667719","phase":"PHASE3","title":"A Long Term Safety Study to Test the Combination of Aliskiren/ Amlodipine / Hydrochlorothiazide in Participants With Essential Hypertension","status":"COMPLETED","sponsor":"Novartis","startDate":"2008-06-05","conditions":"Essential Hypertension","enrollment":564},{"nctId":"NCT04467931","phase":"","title":"ACEI or ARB and COVID-19 Severity and Mortality in US Veterans","status":"COMPLETED","sponsor":"University of Utah","startDate":"2020-01-19","conditions":"Hypertension, COVID","enrollment":22213},{"nctId":"NCT03978884","phase":"PHASE4","title":"Phase 4 Study of the Efficacy of Losartan Based Therapy in Hypertensives With and Without Diabetes","status":"WITHDRAWN","sponsor":"The University of The West Indies","startDate":"2019-06-01","conditions":"Diabetes Mellitus, Hypertension","enrollment":""},{"nctId":"NCT04521023","phase":"PHASE4","title":"A Clinical Trial to Evaluate the Blood Pressure Lowering Effect of a Candemore Plus Tab Versus Cantabell Tab in Hypertensive Patients Inadequately Controlled by Candesartan Monotherapy","status":"COMPLETED","sponsor":"Chong Kun Dang Pharmaceutical","startDate":"2017-09-20","conditions":"Hypertension","enrollment":132},{"nctId":"NCT00765947","phase":"PHASE4","title":"Efficacy and Tolerability of an Aliskiren-based Treatment Algorithm in Patients With Mild to Moderate Hypertension","status":"COMPLETED","sponsor":"Novartis","startDate":"2008-09","conditions":"Essential Hypertension ( Mild to Moderate)","enrollment":256},{"nctId":"NCT00523744","phase":"PHASE3","title":"Efficacy and Safety of Valsartan and Amlodipine (± HCTZ) in Adults With Moderate, Inadequately Controlled Hypertension","status":"COMPLETED","sponsor":"Novartis","startDate":"2007-07","conditions":"Hypertension","enrollment":257},{"nctId":"NCT04330300","phase":"PHASE4","title":"Coronavirus (COVID-19) ACEi/ARB Investigation","status":"SUSPENDED","sponsor":"National University of Ireland, Galway, Ireland","startDate":"2020-04-30","conditions":"Hypertension, COVID-19","enrollment":2414},{"nctId":"NCT03021265","phase":"","title":"To Evaluate Real-world Safety, Effectiveness and Appropriate Use of Micatrio® Combination Tablets Treatment in Patients With Hypertension","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2017-01-20","conditions":"Hypertension","enrollment":676},{"nctId":"NCT02744456","phase":"EARLY_PHASE1","title":"N-of-1 Trials for Blood Pressure Medications in Adults","status":"COMPLETED","sponsor":"Columbia University","startDate":"2014-08-01","conditions":"Hypertension, High Blood Pressure","enrollment":10},{"nctId":"NCT01302691","phase":"PHASE3","title":"MK-0954E Study in Participants With Hypertension (MK-0954E-357)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2011-01-01","conditions":"Hypertension","enrollment":327},{"nctId":"NCT02449811","phase":"","title":"RAS Peptide Profiles in Patients With Arterial Hypertension","status":"COMPLETED","sponsor":"Insel Gruppe AG, University Hospital Bern","startDate":"2015-04","conditions":"Essential Hypertension","enrollment":107},{"nctId":"NCT00902538","phase":"PHASE3","title":"Hydrochlorothiazide as add-on to Olmesartan/Amlodipine in Hypertension","status":"COMPLETED","sponsor":"Daiichi Sankyo","startDate":"2009-04","conditions":"Essential Hypertension","enrollment":2204},{"nctId":"NCT00923091","phase":"PHASE3","title":"Parallel-Group Comparison of Olmesartan (OLM), Amlodipine (AML) and Hydrochlorothiazid (HCTZ) in Hypertension","status":"COMPLETED","sponsor":"Daiichi Sankyo","startDate":"2009-06","conditions":"Essential Hypertension","enrollment":2689},{"nctId":"NCT00649389","phase":"PHASE3","title":"Safety and Efficacy Study of a Triple Combination Therapy in Subjects With Hypertension","status":"COMPLETED","sponsor":"Daiichi Sankyo","startDate":"2008-05","conditions":"Hypertension","enrollment":2500},{"nctId":"NCT01838850","phase":"PHASE3","title":"Efficacy and Safety Study of Olmesartan Medoxomil, Amlodipine and Hydrochlorothiazide Combination Therapy in Patients With Hypertension Not Controlled With Olmesartan Medoxomil and Hydrochlorothiazide Combination Therapy","status":"COMPLETED","sponsor":"Daiichi Sankyo Korea Co., Ltd., a Daiichi Sankyo Company","startDate":"2013-04","conditions":"Essential Hypertension","enrollment":344},{"nctId":"NCT01101009","phase":"PHASE4","title":"Comparison of Sevikar® and the Combination of Perindopril/Amlodipine on Central Blood Pressure","status":"COMPLETED","sponsor":"Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company","startDate":"2010-04","conditions":"Hypertension","enrollment":486},{"nctId":"NCT00220233","phase":"PHASE3","title":"Olmesartan as an add-on to Amlodipine in Hypertension","status":"COMPLETED","sponsor":"Sankyo Pharma Gmbh","startDate":"2005-04","conditions":"Essential Hypertension","enrollment":632},{"nctId":"NCT02412761","phase":"NA","title":"Series of N-of-1 Crossover Trials of Antihypertensive Therapy in Adolescents With Essential Hypertension","status":"COMPLETED","sponsor":"The University of Texas Health Science Center, Houston","startDate":"2013-06","conditions":"Essential Hypertension","enrollment":42},{"nctId":"NCT03578042","phase":"PHASE4","title":"Fixed-Free HTN Trial","status":"UNKNOWN","sponsor":"Hotel Dieu de France Hospital","startDate":"2017-04-01","conditions":"Hypertension","enrollment":100},{"nctId":"NCT01996085","phase":"NA","title":"Non-invasive Haemodynamic Assessment in Hypertension","status":"COMPLETED","sponsor":"Military Institute od Medicine National Research Institute","startDate":"2013-01","conditions":"Arterial Hypertension","enrollment":144},{"nctId":"NCT00994253","phase":"PHASE4","title":"Evaluating the Effect of Aliskiren Versus HCTZ on Coronary Flow Reserve in Hypertensive Type II Diabetics","status":"WITHDRAWN","sponsor":"Corewell Health East","startDate":"2009-08","conditions":"Hypertension, Diabetes Type 2","enrollment":""},{"nctId":"NCT02377661","phase":"PHASE4","title":"Lowering Blood Pressure in Primary Care in Vienna","status":"COMPLETED","sponsor":"Wilhelminenspital Vienna","startDate":"2015-03","conditions":"Hypertension","enrollment":229},{"nctId":"NCT02277691","phase":"PHASE3","title":"A Phase III Long-term Study of TAK-536TCH in Participants With Essential Hypertension","status":"COMPLETED","sponsor":"Takeda","startDate":"2014-11-07","conditions":"Essential Hypertension","enrollment":341},{"nctId":"NCT00438113","phase":"PHASE4","title":"Atrial Substrate Modification With Aggressive Blood Pressure Lowering to Prevent AF","status":"COMPLETED","sponsor":"Nova Scotia Health Authority","startDate":"2009-12","conditions":"Atrial Fibrillation","enrollment":184},{"nctId":"NCT01964079","phase":"PHASE4","title":"Comparision of Blood Pressure Variability Between Amlodipine and Losartan","status":"COMPLETED","sponsor":"Wonju Severance Christian Hospital","startDate":"2013-04","conditions":"Hypertension","enrollment":144},{"nctId":"NCT02433119","phase":"PHASE4","title":"The Efficacy and Safety of OROSARTAN® Versus CODIOVAN® in Patients With Essential Hypertension Uncontrolled With Monotherapy","status":"COMPLETED","sponsor":"Dong-A ST Co., Ltd.","startDate":"2015-03-16","conditions":"Hypertension","enrollment":238},{"nctId":"NCT02129192","phase":"PHASE1","title":"Bioequivalence Study of Telmisartan Between Telmisartan 80 mg/Amlodipine 5 mg/Hydrochlorothiazide 12.5 mg (T80/A5/H12.5 mg) Fixed-dose Combination (FDC) Tablet and T80/H12.5 mg Tab and A5 mg (Encap A2.5 mg Tab x2) Concomitant Use","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2014-05","conditions":"Healthy","enrollment":72},{"nctId":"NCT02294539","phase":"PHASE4","title":"Comparison of Effects Between Amlodipine and Hydrochlorothiazide in Combination With Losartan on 24-hr Central Blood Pressure in Hypertensive Patients","status":"COMPLETED","sponsor":"Chong-Jin Kim","startDate":"2014-08","conditions":"Hypertension","enrollment":231},{"nctId":"NCT01070030","phase":"PHASE4","title":"Efficacy and Safety of Combination Therapy of Aliskiren/Amlodipine or Aliskiren/Amlodipine/Hydrochlorothiazide in Patients With Stage II Hypertension","status":"COMPLETED","sponsor":"Novartis","startDate":"2010-01","conditions":"Stage II Hypertension","enrollment":230},{"nctId":"NCT00219115","phase":"PHASE3","title":"A Clinical Study to Compare Combination of Aliskiren+ HCTZ to Irbesartan+ HCTZ or Amlodipine+ HCTZ or HCTZ Alone in Obese Hypertensive Not Responsive to HCTZ 25 mg","status":"COMPLETED","sponsor":"Novartis","startDate":"2005-01","conditions":"Hypertension","enrollment":493},{"nctId":"NCT01975246","phase":"PHASE3","title":"Add-on to Micamlo BP Trial","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2013-11","conditions":"Hypertension","enrollment":309},{"nctId":"NCT02738632","phase":"PHASE3","title":"Efficacy and Safety of TAH Combination in Comparison With Telmisartan/Amlodipine Combination for Essential Hypertension Patients","status":"COMPLETED","sponsor":"IlDong Pharmaceutical Co Ltd","startDate":"2015-05","conditions":"Essential Hypertension","enrollment":300},{"nctId":"NCT00000620","phase":"PHASE3","title":"Action to Control Cardiovascular Risk in Diabetes (ACCORD)","status":"COMPLETED","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"1999-09","conditions":"Atherosclerosis, Cardiovascular Diseases, Hypercholesterolemia","enrollment":10251},{"nctId":"NCT00360178","phase":"PHASE3","title":"Efficacy and Safety of Valsartan Plus Hydrochlorothiazide in Fixed Dose Combination in Hypertensive Patients Not Controlled by the Free Combination of an Angiotensin Receptor Blocker Plus Hydrochlorothiazide","status":"COMPLETED","sponsor":"Novartis","startDate":"2006-07","conditions":"Hypertension","enrollment":198},{"nctId":"NCT00304226","phase":"PHASE4","title":"Effectiveness of a Valsartan Based Versus an Amlodipine Based Treatment Strategy in naïve Patients With Stage 1 or Stage 2 Hypertension or in Patients Uncontrolled on Current Monotherapy","status":"COMPLETED","sponsor":"Novartis","startDate":"2006-02","conditions":"Hypertension","enrollment":1288},{"nctId":"NCT00666536","phase":"PHASE4","title":"The Effects of Moderate vs. Aggressive Treatment With Valsartan + Amlodipine on Patients With Hypertension Uncontrolled by Angiotensin-Receptor Blocker (Herein, ARB) Monotherapy","status":"COMPLETED","sponsor":"Novartis","startDate":"2008-03","conditions":"Hypertension","enrollment":728},{"nctId":"NCT00787605","phase":"PHASE4","title":"Aliskiren HCTZ Compared to Amlodipine in Patients With Stage 2 Systolic Hypertension and Diabetes Mellitus","status":"COMPLETED","sponsor":"Novartis","startDate":"2008-11","conditions":"Hypertension, Diabetes Mellitus","enrollment":860},{"nctId":"NCT00739596","phase":"PHASE4","title":"Blood Pressure Lowering of Aliskiren Hydrochlorothiazide (HCTZ) Versus Amlodipine in Stage 2 Hypertension in African Americans","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2008-07","conditions":"Hypertension","enrollment":332},{"nctId":"NCT00509470","phase":"PHASE4","title":"Evaluation of Effect of Combination With Telmisartan and Hydrochlorothiazide in Hypertensives Uncontrolled on Amlodipine","status":"COMPLETED","sponsor":"Tokyo University","startDate":"2007-07","conditions":"Essential Hypertension","enrollment":75},{"nctId":"NCT02900729","phase":"PHASE3","title":"Randomized Controlled Trial of Renal Denervation for Resistant Hypertension","status":"UNKNOWN","sponsor":"Shanghai WiseGain Medical Devices Co., Ltd.","startDate":"2016-10","conditions":"Hypertension","enrollment":254},{"nctId":"NCT01365481","phase":"PHASE3","title":"Safety and Tolerability of Valsartan in Children 6 to 17 Years of Age","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2011-08","conditions":"Hypertension, Chronic Kidney Disease","enrollment":150},{"nctId":"NCT01692301","phase":"PHASE2","title":"Study of the Safety and Efficacy of LCZ696 on Arterial Stiffness in Elderly Patients With Hypertension","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2012-12","conditions":"Hypertension","enrollment":454},{"nctId":"NCT01911780","phase":"PHASE3","title":"Compare Efficacy and Safety of Telmisartan/Hydrochlorothiazide With Telmisartan/Hydrochlorothiazide Plus Amlodipine","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2013-07","conditions":"Hypertension","enrollment":132},{"nctId":"NCT01256411","phase":"PHASE2","title":"A Long-term (12 Months) Safety, Tolerability and Efficacy Study of LCZ696 in Patients With Essential Hypertension","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2010-11","conditions":"Essential Hypertension","enrollment":341},{"nctId":"NCT01819220","phase":"PHASE4","title":"Randomized, Open Labeled Clinical Trial to Compare the Effectiveness of Amlodipine/Valsartan vs Hydrochlorothiazide/Telmisartan on Glucose Tolerance in Patients With Hypertension With Metabolic Syndrome","status":"COMPLETED","sponsor":"Yonsei University","startDate":"2009-04","conditions":"Hypertension","enrollment":16},{"nctId":"NCT01922141","phase":"PHASE4","title":"Aliskiren Study of Safety and Efficacy in Senior Hypertensives","status":"WITHDRAWN","sponsor":"Novartis Pharmaceuticals","startDate":"2015-05","conditions":"Hypertension","enrollment":""},{"nctId":"NCT02128386","phase":"","title":"Medication Adherence and \"True\" Resistance in Patients With Resistant Hypertension","status":"UNKNOWN","sponsor":"Charite University, Berlin, Germany","startDate":"2014-02","conditions":"Hypertensive Disease, Hypertension, Resistant to Conventional Therapy","enrollment":50},{"nctId":"NCT00492128","phase":"PHASE4","title":"Kanagawa Combination Anti-hypertensive Therapy (K-CAT)","status":"COMPLETED","sponsor":"Yokohama City University Medical Center","startDate":"2007-09","conditions":"Hypertension","enrollment":196},{"nctId":"NCT01425242","phase":"NA","title":"Study on Anti-inflammatory Effect of Anti-hypertensive Treatment in Patients With Small AAA's and Mild Hypertension","status":"TERMINATED","sponsor":"Amsterdam UMC, location VUmc","startDate":"2011-09","conditions":"Hypertension, Abdominal Aortic Aneurysm","enrollment":3},{"nctId":"NCT01176032","phase":"PHASE4","title":"ALiskiren or Losartan Effects on bioMARKers of Myocardial Remodeling","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2010-06","conditions":"Hypertension, Left Ventricle Hypertrophy","enrollment":74},{"nctId":"NCT01259297","phase":"PHASE3","title":"A Randomized Controlled Trial of Aliskiren in the Prevention of Major Cardiovascular Events in Elderly People","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2011-01","conditions":"Cardiovascular Events","enrollment":2336},{"nctId":"NCT02072330","phase":"PHASE2, PHASE3","title":"Study to Evaluate the Efficacy and Safety of Combined Administration of TAK-536CCB and Hydrochlorothiazide in Patients With Grade I or II Essential Hypertension.","status":"COMPLETED","sponsor":"Takeda","startDate":"2013-03","conditions":"Grade I or II Essential Hypertension","enrollment":353},{"nctId":"NCT00987662","phase":"PHASE4","title":"Irbesartan Versus Amlodipine: The OBI Study","status":"WITHDRAWN","sponsor":"Aristotle University Of Thessaloniki","startDate":"2012-01","conditions":"Obesity, Hypertension","enrollment":""},{"nctId":"NCT01030458","phase":"PHASE4","title":"Newer Versus Older Antihypertensive Agents in African Hypertensive Patients (NOAAH) Trial","status":"COMPLETED","sponsor":"KU Leuven","startDate":"2010-09","conditions":"Blood Pressure","enrollment":183},{"nctId":"NCT01432106","phase":"PHASE1","title":"The Study of Novel Dual Renin Angiotensin Aldosterone System (RAAS) Blockade; Valsartan/Aliskiren in African American Patients With Hypertension and the Metabolic Syndrome","status":"WITHDRAWN","sponsor":"University of Michigan","startDate":"2011-02","conditions":"Hypertension, Metabolic Syndrome","enrollment":""},{"nctId":"NCT00240474","phase":"PHASE4","title":"A Comparison of Telmisartan + Hydrochlorothiazide With Amlodipine + Hydrochlorothiazide in the Control of Blood Pressure in Older Patients With Predominantly Systolic Hypertension (ATHOS Study)","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2002-12","conditions":"Hypertension","enrollment":1000},{"nctId":"NCT01713647","phase":"PHASE1","title":"Bioequivalence Study of Amlodipine / Losartan/ Hydrochlorothiazide of PHARMALINE, Lebanon Under Fastion Conditions","status":"COMPLETED","sponsor":"Pharmaceutical Research Unit, Jordan","startDate":"2012-10","conditions":"Fasting","enrollment":39},{"nctId":"NCT01828359","phase":"PHASE4","title":"The Efficacy and Safety Study of Anti-hypertension Combination Drug in Patients Uncontrolled With Monotherapy.","status":"COMPLETED","sponsor":"Hanmi Pharmaceutical Company Limited","startDate":"2010-08","conditions":"Hypertension","enrollment":199},{"nctId":"NCT00902304","phase":"PHASE4","title":"Valsartan Intensified Primary Care Reduction of Blood Pressure Study","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2009-07","conditions":"Hypertension","enrollment":2337},{"nctId":"NCT01198496","phase":"PHASE4","title":"Recurrent Stroke Prevention Clinical Outcome Study","status":"UNKNOWN","sponsor":"Biomedis International Ltd.","startDate":"2010-10","conditions":"Hypertension, Stroke, Blood Pressure","enrollment":5000},{"nctId":"NCT00834600","phase":"NA","title":"Renin Profiling in Selection of Initial Antihypertensive Drug","status":"COMPLETED","sponsor":"The Louis & Rachel Rudin Foundation","startDate":"2005-12","conditions":"Hypertension","enrollment":185},{"nctId":"NCT00185120","phase":"PHASE4","title":"Treatment of High Blood Pressure Using Olmesartan With Hydrochlorothiazide Compared to an ACE Inhibitor With a Calcium Channel Blocker","status":"COMPLETED","sponsor":"Daiichi Sankyo","startDate":"2005-09","conditions":"Hypertension","enrollment":152},{"nctId":"NCT00171561","phase":"PHASE4","title":"Valsartan/Hydrochlorothiazide Combination vs Amlodipine in Patients With Hypertension, Diabetes, and Albuminuria.","status":"COMPLETED","sponsor":"Novartis","startDate":"2003-03","conditions":"Hypertension","enrollment":144},{"nctId":"NCT00327587","phase":"PHASE3","title":"8-week Study to Evaluate Safety and Efficacy of Various Combinations of Valsartan, HCTZ, and Amlodipine in Patients With Moderate to Severe Hypertension","status":"COMPLETED","sponsor":"Novartis","startDate":"2006-05","conditions":"Hypertension","enrollment":2279},{"nctId":"NCT00171535","phase":"PHASE3","title":"Efficacy and Safety of Valsartan/Amlodipine Combination in Patients With Severe Hypertension","status":"COMPLETED","sponsor":"Novartis","startDate":"2004-10","conditions":"Hypertension","enrollment":130},{"nctId":"NCT00294710","phase":"PHASE3","title":"A Clinical Study to Compare Long-term Efficacy and Safety of an Aliskiren Based Regimen to a Hydrochlorothiazide Based Treatment Regimen With Optional Addition of Amlodipine","status":"COMPLETED","sponsor":"Novartis","startDate":"2005-03","conditions":"Hypertension","enrollment":976},{"nctId":"NCT00797862","phase":"PHASE3","title":"Aliskiren and the Calcium Channel Blocker Amlodipine Combination as an Initial Treatment Strategy for Hypertension","status":"COMPLETED","sponsor":"Novartis","startDate":"2008-11","conditions":"Hypertension","enrollment":1254},{"nctId":"NCT00744237","phase":"PHASE4","title":"Study of the Glycemic Effects of Nebivolol Compared With Metoprolol and HCTZ in Diabetic Hypertensive Patients","status":"COMPLETED","sponsor":"Forest Laboratories","startDate":"2008-08","conditions":"Hypertension, Type 2 Diabetes Mellitus","enrollment":231},{"nctId":"NCT01375322","phase":"PHASE4","title":"ADDM Study - Amtrel and Co-Diovan in Type 2 Diabetes Mellitus Hypertension Patients With Microalbuminuria","status":"COMPLETED","sponsor":"TSH Biopharm Corporation Limited","startDate":"2007-06","conditions":"Hypertension, Diabetes Mellitus, Type 2, Albuminuria","enrollment":226},{"nctId":"NCT00942994","phase":"PHASE4","title":"Aliskiren/Amlodipine/Hydrochlorothiazide (HCTZ) Versus Aliskiren/Amlodipine in US Minority Patients With Stage II Systolic Hypertension","status":"COMPLETED","sponsor":"Novartis","startDate":"2009-06","conditions":"Hypertension","enrollment":412},{"nctId":"NCT00425997","phase":"PHASE4","title":"Efficacy of Valsartan/Hydrochlorothiazide Versus Amlodipine and Hydrochlorothiazide in Patients Hypertension","status":"COMPLETED","sponsor":"Novartis","startDate":"2006-12","conditions":"Hypertension","enrollment":480},{"nctId":"NCT00171054","phase":"PHASE4","title":"Efficacy and Safety of Valsartan Versus Amlodipine in Postmenopausal Women With Hypertension","status":"COMPLETED","sponsor":"Novartis","startDate":"2003-09","conditions":"Hypertension","enrollment":125},{"nctId":"NCT00446563","phase":"PHASE3","title":"Efficacy and Safety of Valsartan in Combination With Amlodipine Compared to Losartan Plus Hydrochlorothiazide in Patients With Hypertension and Left Ventricular Hypertrophy","status":"COMPLETED","sponsor":"Novartis","startDate":"2007-03","conditions":"Hypertension; Hypertrophy, Left Ventricular","enrollment":90},{"nctId":"NCT00765674","phase":"PHASE3","title":"Efficacy and Safety of Aliskiren/Amlodipine/Hydrochlorothiazide in Patients With Moderate-severe Hypertension","status":"COMPLETED","sponsor":"Novartis","startDate":"2008-09","conditions":"Hypertension","enrollment":1191},{"nctId":"NCT00867490","phase":"PHASE3","title":"Safety and Efficacy of Aliskiren + Hydrochlorothiazide (± Amlodipine 5 mg) in Patients With Moderate Hypertension","status":"COMPLETED","sponsor":"Novartis","startDate":"2009-03","conditions":"Hypertension","enrollment":186},{"nctId":"NCT01271374","phase":"PHASE4","title":"Changes in Endothelial Function and Biomarkers in African Americans (AA) With Metabolic Syndrome","status":"UNKNOWN","sponsor":"InVasc Therapeutics, Inc.","startDate":"2010-04","conditions":"Hypertension","enrollment":80},{"nctId":"NCT00760266","phase":"PHASE4","title":"Blood Pressure Lowering of Aliskiren HCTZ Compared to HCTZ in Stage 2 Systolic Hypertension in Older Population","status":"COMPLETED","sponsor":"Novartis","startDate":"2008-09","conditions":"Hypertension","enrollment":451},{"nctId":"NCT01198249","phase":"PHASE1","title":"Pharmacokinetic Drug Interactions Between Single and Concomitant Administrations of Amlodipine, Losartan, and Hydrochlorothiazide in Subjects With (Pre)Hypertension","status":"COMPLETED","sponsor":"Yonsei University","startDate":"2010-09","conditions":"Essential Hypertension","enrollment":23},{"nctId":"NCT00368277","phase":"PHASE3","title":"A Safety and Efficacy Trial of Aliskiren 150mg , 300 mg Compared to Ramipril 5mg, 10mg in the Elderly","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2006-09","conditions":"Hypertension","enrollment":901},{"nctId":"NCT00402103","phase":"PHASE3","title":"An Assessment of Long Term Safety of the Combination of Aliskiren / Amlodipine in Patients With High Blood Pressure","status":"COMPLETED","sponsor":"Novartis","startDate":"2006-11","conditions":"Hypertension","enrollment":556},{"nctId":"NCT00931710","phase":"PHASE4","title":"Valsartan/Amlodipine As Compared to Losartan Treatment in Stage 2 Systolic Hypertension","status":"COMPLETED","sponsor":"Novartis","startDate":"2009-07","conditions":"Stage 2 Systolic Hypertension","enrollment":488},{"nctId":"NCT00311155","phase":"PHASE4","title":"Olmesartan and an add-on Treatment in Patients With Mild to Moderate Hypertension","status":"COMPLETED","sponsor":"Sankyo Pharma Gmbh","startDate":"2006-03","conditions":"Essential Hypertension","enrollment":694}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Amlodipine plus Hydrochlorothiazide","genericName":"Amlodipine plus Hydrochlorothiazide","companyName":"University of Abuja","companyId":"university-of-abuja","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Amlodipine relaxes blood vessels by blocking calcium channels, while hydrochlorothiazide reduces blood volume by increasing sodium and water excretion through the kidneys, together lowering blood pressure. Used for Hypertension.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}